Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Pyxis Oncology Inc (PYXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: PYXS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.2
1 Year Target Price $6.2
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 110.98% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 66.90M USD | Price to earnings Ratio - | 1Y Target Price 6.2 |
Price to earnings Ratio - | 1Y Target Price 6.2 | ||
Volume (30-day avg) 7 | Beta 1.18 | 52 Weeks Range 0.83 - 5.39 | Updated Date 07/2/2025 |
52 Weeks Range 0.83 - 5.39 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.61 |
Earnings Date
Report Date 2025-06-11 | When Before Market | Estimate -0.24 | Actual -0.35 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -29.19% | Return on Equity (TTM) -66.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -17447569 | Price to Sales(TTM) 4.11 |
Enterprise Value -17447569 | Price to Sales(TTM) 4.11 | ||
Enterprise Value to Revenue 5.08 | Enterprise Value to EBITDA 1.09 | Shares Outstanding 61947700 | Shares Floating 44649399 |
Shares Outstanding 61947700 | Shares Floating 44649399 | ||
Percent Insiders 23.41 | Percent Institutions 38.25 |
Upturn AI SWOT
Pyxis Oncology Inc
Company Overview
History and Background
Pyxis Oncology Inc. is a clinical stage oncology company founded in 2019. It focuses on developing next-generation antibody-drug conjugates (ADCs) and immunotherapies to target difficult-to-treat cancers. The company went public in 2021.
Core Business Areas
- Antibody-Drug Conjugates (ADCs): Developing novel ADCs targeting tumor-specific antigens. These ADCs are designed to deliver cytotoxic payloads directly to cancer cells, minimizing damage to healthy tissues.
- Immunotherapies: Developing immunotherapies that enhance the body's immune system to fight cancer. This includes approaches such as bispecific antibodies and other immune-modulating therapies.
Leadership and Structure
Lara S. Sullivan, M.D., is the President and CEO. The company has a board of directors overseeing strategic direction and a management team responsible for daily operations.
Top Products and Market Share
Key Offerings
- PYX-106: PYX-106 is an anti-Siglec-15 antibody designed to block the activity of Siglec-15, an immunosuppressive protein expressed on tumor cells and certain immune cells. It is currently in Phase 1 clinical trials. Competitors include companies developing similar immunotherapies targeting immune checkpoints.
- PYX-201: PYX-201 is an anti-EDB-fibronectin antibody-drug conjugate (ADC) designed to target tumors expressing EDB-fibronectin, an extracellular matrix protein enriched in the tumor microenvironment. It is in preclinical development. Competitors in this space are other companies working on ADCs, such as Seagen (SGEN) and Immunomedics (now part of Gilead, GILD).
Market Dynamics
Industry Overview
The oncology market is a large and rapidly growing market driven by increasing cancer incidence and advancements in treatment options, including targeted therapies and immunotherapies. There is significant competition and high unmet need.
Positioning
Pyxis Oncology is positioned as a company developing novel ADCs and immunotherapies targeting validated cancer targets. Its competitive advantage lies in its differentiated approach to ADC design and immunotherapy development.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars. Pyxis Oncology aims to capture a portion of this market by developing differentiated therapies for specific cancer subtypes.
Upturn SWOT Analysis
Strengths
- Novel ADC and immunotherapy platforms
- Experienced management team
- Focus on validated cancer targets
- Strong intellectual property portfolio
Weaknesses
- Early stage clinical development
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on successful clinical trial outcomes
Opportunities
- Positive clinical trial results could lead to partnerships or acquisitions
- Expansion of pipeline through internal development or licensing
- Address unmet needs in specific cancer subtypes
Threats
- Clinical trial failures
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- GILD
- MRK
- BMY
- AZN
- LLY
Competitive Landscape
Pyxis Oncology is a smaller player in a competitive market. Its advantage lies in its innovative ADC and immunotherapy platforms, but it faces challenges from larger companies with more resources.
Growth Trajectory and Initiatives
Historical Growth: Due to Pyxis Oncology's relative youth as a company, historical growth is primarily reflected in its pipeline development and clinical trial progress.
Future Projections: Future growth depends on the successful completion of clinical trials and potential partnerships or acquisitions. Analyst estimates will vary.
Recent Initiatives: Initiating and advancing clinical trials for lead product candidates, expanding preclinical research programs, and exploring strategic partnerships.
Summary
Pyxis Oncology is a clinical-stage oncology company with a promising pipeline of ADCs and immunotherapies. Its success hinges on favorable clinical trial outcomes. A major risk is failure. The company operates in a highly competitive and regulated market. The company needs to secure more financing for operations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (estimates)
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximations. Financial data may be outdated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pyxis Oncology Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-08 | CEO, President, Chief Medical Officer & Director Dr. Lara S. Sullivan M.D., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.pyxisoncology.com |
Full time employees 44 | Website https://www.pyxisoncology.com | ||
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.